𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial

✍ Scribed by David R. Lynch; Steven M. Willi; Robert B. Wilson; M. Grazia Cotticelli; Karlla W. Brigatti; Eric C. Deutsch; Olena Kucheruk; William Shrader; Patrice Rioux; Guy Miller; Amale Hawi; Thomas Sciascia

Book ID
112143448
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
455 KB
Volume
27
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neurological effects of recombinant huma
Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial
✍ Sylvia Boesch; Brigitte Sturm; Sascha Hering; Barbara Scheiber-Mojdehkar; Hannes 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

## Abstract In a “proof‐of‐concept” study, we demonstrated that recombinant human erythropoietin (rhuEPO) increases frataxin levels in Friedreich's ataxia (FRDA) patients. We now report a 6‐month open‐label clinical pilot study of safety and efficacy of rhuEPO treatment in FRDA. Eight adult FRDA pa

Erythropoietin in Friedreich ataxia: No
Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial
✍ Caterina Mariotti; Roberto Fancellu; Serena Caldarazzo; Lorenzo Nanetti; Daniela 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 844 KB

## Abstract ## Background: Friedreich ataxia is a rare disease caused by GAA‐trinucleotide‐repeat expansions in the frataxin gene, leading to marked reduction of qualitatively normal frataxin protein. Recently, human recombinant erythropoietin was reported to increase frataxin levels in patients w

Measuring the rate of progression in Fri
Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design
✍ Lisa S. Friedman; Jennifer M. Farmer; Susan Perlman; George Wilmot; Christopher 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner‐rated functional